SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk ($NVO) is trending as the community discusses the ongoing bidding war with Pfizer for Metsera, with some questioning the aggressive pursuit given NVO's existing pipeline and others speculating about potential impacts on competition. Community members are also analyzing recent earnings and forward guidance, weighing the potential of upcoming FDA approvals against concerns about management strategy and competition from Eli Lilly.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Unity Software is trending due to positive third-quarter financial results, with revenue and EPS exceeding expectations, sparking bullish sentiment. The community is discussing the company's AI integration and potential beyond just gaming, as well as the growth of Unity Vector. Some investors see the recent earnings as a sign of improved execution and an attractive adtech/fintech ecosystem.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

MannKind ($MNKD) is trending due to recent quarterly results showing increased Afrezza sales and royalties, alongside the completed acquisition of scPharmaceuticals. The community is actively discussing the potential impact on future coverage from Morgan Stanley and Goldman Sachs, as well as updates on clinical trials and revenue projections. Some investors are expressing frustration with the stock's movement despite positive news.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid political chatter and election outcomes, with community members debating the stock's valuation and its ties to narratives and emotion rather than fundamentals. Some traders are pointing to the stock's volatility, while others are highlighting alternative investments with stronger data or enterprise growth. The broader discussion includes contrasting perspectives on the political climate and potential impacts on the market.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is trending amidst analyst optimism and community discussion around its growth strategy, particularly highlighting Needham's updated rating to "Buy". Investors are contrasting ZETA's acquisition approach with other AI players and anticipating an upgrade cycle, while also noting the company's OpenAI partnership. The community is actively debating fundamentals and potential price movements, with some focusing on its ability to quietly add enterprise clients and deliver measurable growth.

Digital Turbine, Inc. is a mobile growth platform that offers solutions for advertisers, publishers, carriers, and device original equipment manufacturers (OEMs). The firm operates through the On Device Solutions (ODS) and App Growth Platform (AGP) segments. The ODS segment generates revenue from the delivery of mobile application media or content to end users with solutions for all participants in the mobile application ecosystem that want to connect with end users and consumers who hold the device. This includes mobile carriers and device OEMs that participate in the app economy, app publishers and developers, and brands and advertising agencies. The AGP segment provides platforms that allow mobile app publishers and developers to monetize their monthly active users via display, native, and video advertising. The company was founded on November 6, 1998 and is headquartered in Austin, TX.

Digital Turbine Inc

APPS is trending due to positive sentiment around its potential to capitalize on the changing app store landscape after recent rulings, with community members discussing possible revenue boosts and increased valuations. Some are pointing towards a potential run to double digits, and short squeezes. Also named as being a top value stock, the company is being closely watched for its ability to leverage AI and partnerships.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart is trending due to recent earnings and concerns about its loan portfolio, sparking debate among investors. While some believe Upstart's AI-driven lending model positions it for long-term growth, others fear a potential credit crunch and the impact of macro factors. The community is actively discussing management's strategy and the company's ability to navigate the current economic climate.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending amid mixed sentiment following recent Q3 earnings and key strategic updates, including reaffirmed timelines for the R2 launch and the introduction of Mind Robotics. While some community members express bullish views on long-term potential, others remain skeptical about profitability and execution, particularly regarding the R2's success. Discussions also revolve around Rivian's positioning in the EV market relative to competitors like Tesla, as well as potential impacts from partnerships and industry trends.

What is Chromia? Chromia is an open source public blockchain conceived of by Swedish company Chromaway AB. The Chroma token (CHR) was launched in May of 2019. The technology behind the Chromia blockchain is adapted from an earlier technology called ‘Postchain’, a solution provided by Chromaway AB for enterprise clients.   How does Chromia work? Chromia is a standalone Layer-1 blockchain and EVM compatible Layer-2 enhancement for Binance Smart Chain and Ethereum. It is designed to enhance existing dApps and allow for the creation of next-generation dApps by providing scalability, improved data handling, and customizable fee structures. The blockchain uses a unique architecture called relational blockchain, as well as a custom programming language called Rell.  Rell is designed to code and function very similarly to SQL, allowing developers to leverage the security and immutability of blockchain while storing and handling data with the efficiency of a relational database.  Each dApp running on Chromia operates on its own sidechain which is rooted in the main blockchain. This allows each application to scale more efficiently and gives each application developer the freedom to choose from a variety of fee structures. For example, one application may require users to pay transaction fees in CHR (similar to how Ethereum or Bitcoin work), while another application could stake enough CHR to reserve computational power and allow their users to make unlimited transactions without paying any fees at all.   What applications have been built on Chromia? Chromia already has a wide variety of applications building upon their blockchain, using their chain as a decentralized storage layer, and using their Layer-2 enhancements. These applications range from DeFi options trading platform Hedget, to open world farming game My Neighbor Alice, to government land registry initiative LAC PropertyChain.  One of the latest features in development is a new NFT standard called Chromia Originals, which will operate both as a native standard on Chromia’s chain as well as an enhancement layer for existing ERC-721 and BEP-721 tokens. Work on these Layer-2 enhancements are being developed in cooperation with My Neighbor Alice.  Who is behind Chromia? Chromia’s core team consists of industry veterans Or Perelman, Henrik Hjelte and Alex Mizrahi. All three have deep roots in the crypto space, going back to the early days of Bitcoin and Ethereum. For example, Alex published several early academic papers on Proof of Stake consensus and was also one of the key figures behind Colored Coins, one of the first projects to develop the idea of ‘tokens’ that would later be brought to prominence by Ethereum.  In summary, Chromia is a Layer-1 and Layer-2 blockchain solution under active development, with the goal of delivering enhanced features and data handling and storage capabilities to decentralized applications.

Chromia

Chromia is trending amid discussions of potential buyout offers, with community members highlighting proposed prices per share. Some investors are also drawn to its financials, including reported cash reserves and book value, while others are excited about the future potential of the project as the leading blockchain for gaming.

DigitalOcean Holdings, Inc. engages in the provision of providing cloud infrastructure. It operates through the following geographical segments: United States, Netherlands, Germany, Canada, Singapore, and Other. The company was founded in 2012 and is headquartered in Broomfield, CO.

DigitalOcean Holdings Inc

DigitalOcean ($DOCN) is trending as investors react positively to strong earnings, with revenue growth and AI initiatives driving excitement. The community highlights the company's focus on SMBs and its potential as an acquisition target, fueling discussions about its long-term growth prospects. Bullish sentiment is further supported by positive analyst ratings and price target increases.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$SANA anyone who thought they missed the move, this is your buying opportunity. Literally nothing has changed about this company between when it was trading at $6 and now at $4.50. People were giving me so much crap when the stock dropped 30% to $3 after their secondary offering, yet here we are trading higher (even now still up 50% from the post-secondary offering price). As I said back then, and as I still say now, cooler heads will prevail. The math doesn&#39;t lie, the stock is still undervalued. I think we&#39;re in the goldilocks buying zone. We&#39;re about a year away from phase 1 SC451 data. I can&#39;t envision the stock not trading several multiples higher from here leading up to and/or after that data is released. Barring another market crash, the risk/reward is about as good as it will ever be right now.

Mirko papuga

John Bednar

$SANA bla bla bla bag holders talking shit as if their company was relevant, biotech are GAMBLING, just look at those Sarepta guys, they learned the hard way their product was 100% BS, not better than placebo, and yet they refuse to acknowledge it and keep the rocket ship emojis.... pathetic sore losers same as SANA

StockTwits Web

Sana Biotechnology Inc

 anyone who thought they missed the move, this is your buying opportunity. Literally nothing has changed about this company between when it was trading at $6 and now at $4.50. People were giving me so much crap when the stock dropped 30% to $3 after their secondary offering, yet here we are trading higher (even now still up 50% from the post-secondary offering price). As I said back then, and as I still say now, cooler heads will prevail. The math doesn't lie, the stock is still undervalued. I think we're in the goldilocks buying zone. We're about a year away from phase 1 SC451 data. I can't envision the stock not trading several multiples higher from here leading up to and/or after that data is released. Barring another market crash, the risk/reward is about as good as it will ever be right now.

LunarPixel87

@LunarPixel87 we are not a year away from SC451 data.  We are a year away from the start of the trial.  We have no idea about the trial protocol.  How many patients; how long before data released, etc.  It easily could be 18 months before SC451 data.  Sorry to quibble.

T Tyler

StockTwits for iOS

 we are not a year away from SC451 data.  We are a year away from the start of the trial.  We have no idea about the trial protocol.  How many patients; how long before data released, etc.  It easily could be 18 months before SC451 data.  Sorry to quibble.

Jerry Malone

@JerryMalone32 CEO said once they get IND approval, would start trials in about a month. Then they will release 1 month data like they did in uppsala trial. So from IND approval to data, you&#39;re looking at 2 months. 18 months is a bit too long. I&#39;m expecting IND approval by mid next year. 2 months from that is about a year from now.

 CEO said once they get IND approval, would start trials in about a month. Then they will release 1 month data like they did in uppsala trial. So from IND approval to data, you're looking at 2 months. 18 months is a bit too long. I'm expecting IND approval by mid next year. 2 months from that is about a year from now.

@LunarPixel87 $SANA   lot of guesswork.  We have no idea how long it will take to enroll 40-80 patients.  Even if the first is enrolled that first day.  They may want to stagger the enrollments, test multiple doses, etc.  They may not release data like they did with UP421 because there could be 80 patients with staggered start times and different doses.  It could be 6 months to a year before data.  We have no idea.  I think it would behoove you to not guess and just wait until the trial protocol is published.

   lot of guesswork.  We have no idea how long it will take to enroll 40-80 patients.  Even if the first is enrolled that first day.  They may want to stagger the enrollments, test multiple doses, etc.  They may not release data like they did with UP421 because there could be 80 patients with staggered start times and different doses.  It could be 6 months to a year before data.  We have no idea.  I think it would behoove you to not guess and just wait until the trial protocol is published.

he was pretty explicit in his talk that they would be in patients in about a month after IND approval. Big question is when will IND be approved. He basically said &quot;when it happens&quot; when asked that. But they are definitely going to be moving as quick as possible since they only raised a year of cash. I think a year is a reasonable guess, but yea, it&#39;s a bit of a guess. I think they&#39;re extremely incentivised to release data as quick as possible.

he was pretty explicit in his talk that they would be in patients in about a month after IND approval. Big question is when will IND be approved. He basically said "when it happens" when asked that. But they are definitely going to be moving as quick as possible since they only raised a year of cash. I think a year is a reasonable guess, but yea, it's a bit of a guess. I think they're extremely incentivised to release data as quick as possible.

@LunarPixel87 I&#39;d echo that and also add SANA is in a better position than when I first bought late May &#39;25 with an equity offering completed and is now good on cash for the next few quarters, writing off the manufacturing assets that were going to cost huge cash outflows ... worst has to be behind us now... I bought last week thinking $5.45 was a good deal, but $4.55 today is an even better buy!

 I'd echo that and also add SANA is in a better position than when I first bought late May '25 with an equity offering completed and is now good on cash for the next few quarters, writing off the manufacturing assets that were going to cost huge cash outflows ... worst has to be behind us now... I bought last week thinking $5.45 was a good deal, but $4.55 today is an even better buy!

@mirko_papuga i added today for sure, nonsense move

@LunarPixel87 no, you are wrong.  He did not say a month.  He said the first patient would be treated within “hours” of getting IND clearance.  But that is not the issue.  It isn’t when the first patient is treated.  UP421 was N =1.  SC451 N = ??   There will be different doses for sure.  And you have no idea how long it will take to go through all the doses, nor how much follow-up.  I am not assuming to know anything until the trial starts and the protocol is published.

 no, you are wrong.  He did not say a month.  He said the first patient would be treated within “hours” of getting IND clearance.  But that is not the issue.  It isn’t when the first patient is treated.  UP421 was N =1.  SC451 N = ??   There will be different doses for sure.  And you have no idea how long it will take to go through all the doses, nor how much follow-up.  I am not assuming to know anything until the trial starts and the protocol is published.

@JerryMalone32 yea, he didn&#39;t say explicitly 1 month, I relistened. He said he ruled out places that will take 3+ months. So to me that&#39;s like 1 month in my mind. He also mentioned things like a potential 1 month delay due to irb meeting. I still think they will release 1 month data. He said he didn&#39;t know if they would do that yet, but i don&#39;t see why they wouldn&#39;t. 2 months to data post ind approval still seems a reasonable guess to me. The point is it&#39;s coming up soon. Not going to be 2 years.

 yea, he didn't say explicitly 1 month, I relistened. He said he ruled out places that will take 3+ months. So to me that's like 1 month in my mind. He also mentioned things like a potential 1 month delay due to irb meeting. I still think they will release 1 month data. He said he didn't know if they would do that yet, but i don't see why they wouldn't. 2 months to data post ind approval still seems a reasonable guess to me. The point is it's coming up soon. Not going to be 2 years.

@LunarPixel87 Guess we both added to positions too early. Down several tens of thousands, but not adding anything yet - momentum seems to be on a serious downward trend, for now at least. Someone asked Buffet when the market went down precipitously, how much $$$ he had lost. None, I didn&#39;t sell, was his reply! Holding onto every share - after two months of no news, there should be quite a bit to listen to!

 Guess we both added to positions too early. Down several tens of thousands, but not adding anything yet - momentum seems to be on a serious downward trend, for now at least. Someone asked Buffet when the market went down precipitously, how much $$$ he had lost. None, I didn't sell, was his reply! Holding onto every share - after two months of no news, there should be quite a bit to listen to!